17132
Targeted agents currently approved or under investigation for SCCHN include epidermal growth factor receptor ( EGFR ) monoclonal antibodies ( cetuximab , panitumumab , zalutumumab , nimotuzumab ) , EGFR tyrosine kinase inhibitors ( gefitinib , erlotinib , lapatinib , afatanib , dacomitinib ) , vascular endothelial growth factor receptor ( VEGFR ) inhibitors ( bevacizumab , sorafenib , sunitinib , vandetanib ) and various inhibitors of other pathways and targets , including phosphatidylinositol 3 ' kinase ( PI3K ) / AKT / mammalian target of rapamycin ( mTOR ) , MET and insulin - like growth factor receptor ( IGF - 1R ) .
 Chemical: tyrosine; Chemical: gefitinib; Chemical: erlotinib; Chemical: lapatinib; Chemical: afatanib; Chemical: dacomitinib; Chemical: sorafenib; Chemical: sunitinib; Chemical: vandetanib; Chemical: phosphatidylinositol; Chemical: rapamycin
Please list all entity words in the text that fit the category.Output format is "type1: word1; type2: word2". 
Option: Chemical 
Text: {0} 
Answer:
 Chemical: tyrosine; Chemical: gefitinib; Chemical: erlotinib; Chemical: lapatinib; Chemical: afatanib; Chemical: dacomitinib; Chemical: sorafenib; Chemical: sunitinib; Chemical: vandetanib; Chemical: phosphatidylinositol; Chemical: rapamycin